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Key Points 
Question: What items should be reported to allow readers to evaluate the validity and 
applicability and to enhance the replicability of diagnostic test accuracy (DTA) 
systematic reviews? 
Findings: This guideline is an extension of the PReferred Items for reporting Systematic 
Reviews and Meta-Analyses (PRISMA): PRISMA-DTA. Two PRISMA items have been 
omitted, two added, and 17 were modified to reflect DTA-specific or optimal 
contemporary systematic review methods. 
Meaning: PRISMA-DTA can facilitate transparent reporting of DTA reviews, and may 
help assist evaluations of validity and applicability, enhance replicability of reviews, and 
make the results more useful for clinicians, journal editors, reviewers, guidelines-authors 
and funders.  
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Abstract  
IMPORTANCE: Diagnostic test accuracy (DTA) systematic reviews synthesize data 
from primary diagnostic studies that have evaluated the accuracy of one or more index 
tests against a reference standard.  DTA systematic reviews provide estimates of test 
performance, allow comparisons of the accuracy of different tests, and facilitate the 
identification of sources of variability in test accuracy.   
OBJECTIVE: To develop PRISMA-DTA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) as a stand-alone extension of the PRISMA Statement, 
modified to reflect the particular requirements for reporting DTA systematic reviews and 
meta-analyses, as well as PRISMA-DTA for abstracts.   
DESIGN: Established standards for guideline development (EQUATOR Network) were 
followed. The PRISMA-Statement was used as a framework upon which to modify and 
add material.  A group of 24 multi-disciplinary experts used a systematic review of 
existing reporting guidelines and methods articles, a 3-round Delphi process, a consensus 
meeting, pilot testing, and iterative refinement to develop PRISMA-DTA.  The final 
version of the PRISMA-DTA checklist was approved by the PRISMA-DTA group. 
FINDINGS: Systematic review (64 items) and Delphi feedback (six new items proposed 
and one item split into two) identified 71 potentially relevant items for consideration; the 
Delphi process reduced these to 60 items that were discussed at the consensus meeting.  
Following the meeting, piloting and iterative feedback was used to generate the 27-item 
PRISMA-DTA checklist.  To reflect DTA-specific or optimal contemporary systematic 
review methods, 8 of the 27 original PRISMA items were left unchanged, 17 were 
modified, 2 were added and 2 omitted.   
CONCLUSIONS AND RELEVANCE: PRISMA-DTA provides specific guidance for 
reporting of DTA systematic reviews.  PRISMA-DTA can facilitate transparent reporting 
of DTA reviews, and may assist evaluations of validity and applicability, enhance 
replicability of reviews, and make the results more useful for multiple stakeholders. 
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Introduction 
Systematic reviews can advance understanding of diagnostic test accuracy (DTA). DTA 
systematic reviews synthesize data from primary studies to provide insight into the ability 
of medical tests to detect a target condition—they can provide estimates of test 
performance, allow comparisons of the accuracy of different tests, and facilitate the 
identification of sources of variability1. The number of DTA systematic reviews has 
increased rapidly; however, they are often not reported completely, which has contributed 
to “a crisis of repeatability”2-5. 
Reporting of systematic reviews should be complete and informative to enable 
readers to assess the quality of methods and validity of findings. Published DTA 
systematic reviews are often not informative, and are of heterogeneous quality4,6,7. They 
demonstrate variability in approaches to fundamental methodological steps, including 
methods to assess risk of bias, assessment of between-study variability, and methods for 
combining data across studies7-11.   
To improve reporting of systematic reviews, the Preferred Reporting Items for 
Systematic-Reviews and Meta-Analyses (PRISMA) guideline was published (27-item 
checklist and flow-diagram)13.  PRISMA was directed at systematic reviews of 
interventions; the authors suggested modification for DTA reviews 14. Though DTA 
systematic-reviews share elements with those of interventions, there are important 
differences. Study-design and measures of effect differ from those of randomized-trials.  
Accuracy can differ between studies due to differences in patients, setting, prior testing 
and use of different reference standards. Consequently, methods for evaluating risk of 
bias, summarizing results, and exploring variability differ from those used for 
interventions.  As such, some PRISMA-items are not appropriate for DTA systematic 
reviews, others need adaptation, and some areas may not be covered1,15,16.   
We aimed to develop PRISMA-DTA as a stand-alone extension of PRISMA, 
modified to reflect the particular requirements for reporting DTA systematic reviews. A 
secondary objective was to identify items that should be included in abstracts of DTA 
systematic reviews (PRISMA-DTA for Abstracts). 
 
Methods 
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This study was determined to be exempt from IRB-review.  After establishing the 
PRISMA-DTA executive group, comprised of the lead author of PRISMA (DM) 13, the 
lead author of STARD (Standards for the Reporting of Diagnostic Accuracy Studies) 
(PMMB) 17 and an experienced author, reviewer and editor of DTA systematic reviews 
(MDFM), a number of experts were contacted to join the PRISMA-DTA group and assist 
with the project (all contacted experts agreed to participate). The goal was to assemble a 
team of experts in DTA research and systematic review methods, complemented by DTA 
systematic review authors, journal editors, funders, and DTA systematic review users. 
eTable 1 lists the 24 members and their relevant expertise of the PRISMA-DTA group.  
The PRISMA-DTA executive registered the protocol for developing the statement 
with the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) 
network 19. The protocol was based on previously published guidance for establishing 
reporting guidelines, created by the EQUATOR network; no major deviations from the 
protocol occurred 20. The PRISMA-DTA group used the standard PRISMA statement 13 
as a starting point and endeavored to identify items that needed to be added, removed or 
modified to meet the needs of DTA systematic reviews. 
Details of the systematic review for item generation have been published 
elsewhere21. Briefly, searches of multiple databases and existing sources of guidance for 
reporting of systematic reviews and DTA studies (e.g. PRISMA, STARD 2015) 13,17 were 
performed to identify articles pertaining to methodology or reporting quality of DTA 
systematic reviews. Following data extraction from these reports, potential PRISMA-
DTA items were categorized according to specific reporting topics: general overview, 
quality of reporting, search, variability, pooling methods, publication bias, risk of bias, 
and ‘other’.   This list of potential PRISMA-DTA items was presented in the first round 
of the Delphi procedure. 
 
Delphi Procedure 
A three-round Delphi process was held between December 2016-March 2017, in which 
all members of the PRISMA-DTA group were invited to participate 22,23. This modified 
Delphi process has been used previously for similar work such as: Risk of Bias in 
Systematic reviews (ROBIS) and STARD 2015 24,25. The aim of the process was to 
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achieve consensus on essential items that should make up PRISMA-DTA and to identify 
items that required discussion at the consensus meeting.  
During each round of the survey, potential essential items were proposed, and 
participants were asked to score each item on a 1-5 Likert scale, anchored at (1) “not 
essential to report in a systematic review of diagnostic test accuracy studies” and (5) 
“essential to report in a systematic review of diagnostic test accuracy studies”.  Likert 
scores were categorized as: 1-2 = low score (item should not be part of PRISMA-DTA), 3 
= moderate (item should be discussed), 4-5 = high score (item should be part of 
PRISMA-DTA). For an item to meet ‘consensus’, more than 66% of the Delphi 
respondents needed to rate one of these three categories; this threshold is based on that 
used for previous reporting guidelines26. 
During round 1 of the Delphi survey, all items identified during the systematic 
review step were proposed21. Participants were also asked to suggest any additional items 
that were potentially relevant to report in systematic reviews of DTA studies. Round 2 of 
the survey included any items that did not reach consensus in round 1, and any new items 
suggested by at least 1 respondent in round 1. As with round 2, round 3 involved items 
that did not reach consensus in rounds 1 or 2. 
Following each of the three rounds, the mode (most frequent) score for each item 
was tabulated. Items were categorized as follows: a) mode score 1-3 but <66% of 
participants: proceed to next round of Delphi (or to meeting discussion if Delphi round 
3), b) consensus score 1 or 2:  do not include; c) consensus score 3: discuss at meeting; d) 
mode score 4 or 5 but for <66% of participants: discuss at meeting; e) consensus score 4 
or 5: include in PRISMA-DTA (but discuss at meeting to confirm exact wording). All 
participants were provided an anonymized summary of the results after each round of the 
process.  SurveyMonkey (SurveyMonkey Inc, San Mateo, California, USA) was used to 
administer the survey. 
 
Consensus meeting  
A two-day consensus meeting was held in Amsterdam, The Netherlands in May, 2017; 
all members of the executive and PRISMA-DTA group were invited to attend. The main 
objective of this meeting was to agree on items for which no consensus was reached 
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during the Delphi survey, to generate a preliminary PRISMA-DTA checklist (and 
PRISMA-DTA for abstracts). For the items that reached consensus for inclusion prior to 
the meeting, precise wording of items was decided. 
 
Checklist Pilot  
Following the meeting, members of the PRISMA-DTA group reviewed and applied the 
checklist to ongoing DTA systematic reviews in order to identify any practical challenges 
with any of the items and to inform writing of the statement. This included formal 
piloting of the preliminary checklist on published DTA systematic reviews by a graduate 
student (JPS).  In addition, multiple potential users and stakeholders were invited to 
review and apply the preliminary checklist in order to assess utility and clarity of 
wording. Feedback from these pilot exercises was used to refine wording and 
presentation of the checklist.  Formal feedback was gathered via a survey administered 
via SurveyMonkey (SurveyMonkey Inc, San Mateo, California, USA); this was sent to 
the entire PRISMA-DTA group.  Additional feedback was gathered via email 
correspondence.  All sources of feedback were used to modify and inform the final 
version of the PRISMA-DTA checklist. 
 A further explanation and elaboration document (E&E) will subsequently be 
developed to provide additional detail regarding the rationale for items and examples. 
 
Results 
Delphi procedure 
Participation in the Delphi survey is documented in eTable 1; 23 individuals completed 
all 3 rounds of the survey. In Round 1, the group evaluated 64 items identified by the 
systematic review: 42 items met consensus for inclusion, 20 items moved forward to 
round 2, 2 items were excluded, and an additional 6 items were suggested for inclusion 
for round 2.  In Round 2, the group assessed 27 items (1 item from round 1 was split into 
2): 5 items met consensus for inclusion, 15 items moved forward to round 3, and 7 items 
were excluded.  In Round 3, no item met consensus for inclusion, 13 items were moved 
forward to the consensus meeting, and 2 items were excluded. Overall, after 3 Delphi 
rounds, 47 items were included (final wording to be discussed at the face-to-face 
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consensus meeting), 13 items moved forward to the consensus meeting to discuss 
inclusion or exclusion, and 11 items were excluded. A list of the 11 excluded items is 
provided in eTable 2.  While these items are considered relevant to reporting of DTA 
systematic reviews, they were felt to be either too detailed for a ‘minimum reporting 
guideline’ or not relevant depending on the scope or purpose of the review. Several of 
these items will be further discussed in the forthcoming Explanation and Elaboration 
document.  Flow diagram documenting the Delphi procedure is provided in Figure 1. 
 
Consensus Meeting 
Meeting attendance (n = 18) and the agenda are documented in eTables 1 and 3 
respectively.  Of the 60 items discussed at the meeting, 27 were excluded. Excluded 
items and the rationale for exclusion are provided in eTable 2.   
Two of the 27 items of the original PRISMA checklist were confirmed for 
removal: items 15 and 22. These items refer to evaluation for and reporting of risk of bias 
that may affect the cumulative evidence such as publication bias and selective reporting 
within studies. These were excluded for two main reasons. First, there is only limited 
evidence that publication or reporting bias is a major issue for primary DTA studies27,28. 
As such, the rationale for mandating its evaluation in DTA systematic reviews is not as 
strong as for intervention reviews. Second, there is no appropriate test with adequate 
statistical power to reliably assess publication bias in the context of DTA systematic 
reviews 29-31.   
The remaining 33 items were discussed and synthesized into a draft PRISMA-
DTA checklist; many of the items were combined in order to reduce redundancy between 
and minimize the total number of items.  The PRISMA flow diagram was also reviewed 
at the consensus meeting and no modifications for PRISMA-DTA were deemed 
necessary. 
Compared to the original PRISMA checklist, two new items were added. Item 
D1: State the scientific and clinical background, including the intended use and 
clinical role of the index test, and if applicable, the rationale for minimally acceptable test 
accuracy (or minimum difference in accuracy for comparative reviews). The rationale for 
inclusion is two-fold. First, the role of the index test is critical to understanding the place 
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of a test in the diagnostic pathway; diagnostic accuracy can vary importantly depending 
on the clinical scenario. Without this information, generalizability of the results to the 
clinical setting may be limited 17,18.  Second, identifying minimum acceptable test 
accuracy may be helpful in forming conclusions. Whether a test is considered clinically 
useful cannot be determined by a diagnostic accuracy measure alone; its accuracy relative 
to alternative tests or management strategies must be considered, as well as the 
downstream consequences of false positives and false negatives. As such, considering 
external evidence to form criteria for minimum acceptable test standards may play an 
important role in forming the purpose of DTA systematic reviews 12,17,18.   
Defining a minimally acceptable test accuracy (or minimum difference) may not 
always be appropriate depending on the review question.  For example, if a test is not yet 
well established or understood, the purpose of the review might be to evaluate reasons for 
variability in accuracy.  For this reason, we have added the qualifier ‘if applicable’ to this 
item. 
The second new item was D2: Report the statistical methods used for meta-
analyses, if performed. Meta-analyses of DTA studies typically require multivariate 
models (e.g. bivariate and hierarchical summary ROC) which allow for the trade-off 
between sensitivity and specificity due to positivity threshold, for potential correlation 
between estimates of sensitivity and specificity across studies and for variability through 
the inclusion of random effects 32,33. Traditional univariate methods ignore this 
correlation and can give misleading results 5,34,35.  We acknowledge that there are 
instances when univariate methods may be appropriate, for example if the specificity of a 
test is set at 100%, and univariate meta-analysis of sensitivity is the focus of the review.   
As such, reporting the method used for meta-analysis (if done) was considered essential 
for DTA systematic reviews. 
Eight of the original PRISMA items were not modified since they were felt to be 
equally applicable to systematic reviews of DTA (Original PRISMA items: 3, 5, 7, 9, 10, 
16, 17 and 27).   
Seventeen of the original PRISMA items were adapted: (items 1, 2, 4, 6, 8, 11-14, 
18-21, and 23-26). The reason for modification varied—the two major reasons were 
either that there was unclear or ambiguous wording in the original PRISMA statement 
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that required updating or that wording specific to issues for DTA systematic reviews was 
necessary. Table 1 lists the rationale for modification of the original PRISMA items for 
PRISMA-DTA. Further explanation and elaboration on the rationale and evidence will be 
provided in the forthcoming Explanation & Elaboration document.    
 At the consensus meeting, PRISMA for Abstracts was modified to arrive at 
PRISMA-DTA for Abstracts 36. The total number of items (n=12) was preserved. Five 
items were not modified (Items 4, 6, 10-12). One item was deleted (Item 8- description of 
the effect) since effect size is only relevant to interventions, and not DTA studies 1,29.  
One new item was added (A1. Synthesis of results); this corresponds to new item D2 in 
PRISMA-DTA. Six items were modified (Items 1-3, 5, 7 and 9) to reflect the modified 
language for the corresponding items in PRISMA-DTA (as described in Table 1 and 
above). 
 
Piloting & Revision  
Thirty-seven points of feedback from the pilot exercise were received via email and 
formal survey.   This feedback was considered by the PRISMA-DTA executive group 
and used to modify five of the items, as well as to add further explanation and rationale.  
 
Final Checklists 
The final version of the PRISMA-DTA checklist is provided in Table 2. PRISMA-DTA 
has the same number of items as PRISMA; 2 original items were deleted (items 15 and 
22) and 2 new items were added.  Numbering from the original PRISMA statement is 
preserved; the 2 new items are labelled: D1 and D2. 
The final version of the PRISMA-DTA for Abstracts checklist is provided in 
Table 3.  PRISMA-DTA for abstracts has the same number of items as PRISMA for 
abstracts (n=12) One item was deleted (item 8) and one new item was added.  Numbering 
from the original PRISMA for abstracts is preserved; the new item is labelled: A1.  
 
Discussion 
PRISMA-DTA is a reporting guideline providing guidance specific to DTA systematic 
reviews. Both the PRISMA-DTA statement and  PRISMA-DTA for Abstracts were 
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developed with multidisciplinary consensus approaches as per best practices for guideline 
development 20. PRISMA-DTA items reflect the concepts, methodology and language 
specific to DTA systematic reviews and, if implemented, can help ensure that information 
for assessment of risk of bias and applicability in DTA research is reported, and can 
enhance transparency and replicability of DTA systematic reviews. This work should be 
of practical use to multiple stakeholders, who author, review, publish, fund and 
implement results of DTA systematic reviews; it may also be useful as a guidance for 
DTA systematic review protocols.  DTA systematic reviews for which this checklist is 
relevant include evaluation of single tests, multiple tests (comparative), and multivariable 
diagnostic models.   
PRISMA-DTA aims to improve completeness and transparency of reporting of 
DTA systematic reviews.  Complete reporting might be associated with review quality, 
however, they are not inseparable 4. Understanding and application of optimal DTA 
systematic review principles and methods is fraught with complexity and pitfalls—it 
cannot all be learned from a 27-item reporting checklist 1. While guidance is available for 
conducting DTA systematic reviews 29, considerable areas of uncertainty remain (e.g. 
optimal methods for assessing variability, appropriate interpretation of review findings); 
these areas are likely to evolve based on ongoing and future research 8. As such, 
prospective reviewers are encouraged to seek specialized training (e.g. Cochrane 
Screening and Diagnostic Tests Methods Group author training resources) and to 
collaborate with those experienced in DTA systematic review methods37. 
Conforming to reporting guidelines can be challenging based on journal-level 
constraints such as limits on words, tables and figures although there is little evidence to 
indicate that reporting guidelines increase article word length. Methods to ensure 
complete reporting may include the use of supplementary on-line only material, 
institutional repositories and appendices. PRISMA-DTA represents minimum reporting 
requirements, rather than a constraint or cap on what should be reported. Additional 
information that authors consider relevant to their specific review question may also be 
reported (e.g. inter-observer agreement for imaging reviews).   Complete reporting of 
DTA systematic reviews may be hindered by incomplete reporting in DTA primary 
studies38.  This challenge makes complete reporting of DTA systematic reviews all the 
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more important since readers need to know whether necessary information from the 
primary studies was available from which conclusions can be drawn. 
 
Limitations 
The PRISMA-DTA project was guided by evidence-based principles where possible; 
however, when evidence was lacking, expert opinion was relied upon.  PRISMA-DTA 
was designed for all types of DTA research; some specialties (e.g. imaging) may have 
important items unique to their specialty (e.g. inter-observer agreement) that are not 
included in PRISMA-DTA and should be reported.  Finally, as the body of evidence in 
DTA research grows, PRISMA-DTA will need to be updated to reflect these advances. 
 
Conclusion 
PRISMA-DTA provides specific guidance for reporting of DTA systematic 
reviews.  PRISMA-DTA can facilitate transparent reporting of DTA reviews, and may 
assist evaluations of validity and applicability, enhance replicability of reviews, and make 
the results more useful for multiple stakeholders. 
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Note to reviewers/ editors:  the text box below is a suggested stand-alone summary of 
changes to be included in the paper. 
 
 
  
FROM PRISMA TO PRISMA-DTA:  HOW DID PRISMA 
ITEMS CHANGE? 
PRISMA ITEMS REMOVED (2) 
Item 15:  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies). 
Item 22:  Present results of any assessment of risk of bias across studies .   
 
PRISMA ITEMS MODIFIED (17) 
Items 1, 2, 4, 6, 8, 11-14, 18-21 and 23-26.  
 
NEW ITEMS (2) 
D1: State the scientific and clinical background, including the intended use and clinical role of the index 
test, and if applicable rationale for minimally acceptable test accuracy (or minimum difference in 
accuracy for comparative design). 
D2: Report the statistical methods used for meta-analyses, if performed.   
 
Details and rationale for removal, modifications and additions are provided in the text and appendices. 
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Figure Legends 
Figure 1: Study flow diagram documenting the Delphi Procedure. 
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Table 1: Rationale for modification of original PRISMA items for PRISMA-DTA.   
Note: final wording for items is provided in Tables 2 and 3.  
Item Reason for modification 
1. Title Specification that the systematic review pertains to ‘diagnostic accuracy’ in the title is felt to enhance clarity 
of purpose and allow for easy identification when searching for reviews. 
2. Abstract/ 
Structured 
summary 
As per our study objectives, we aimed to create a specific, essential list of items for DTA systematic 
reviews to be reported in the abstract.  As such, we replaced this item with PRISMA-DTA for abstracts 
(Table 3). 
4. Objectives The original PRISMA wording (Participant, Intervention, Comparison, Outcome, PICO) was intended for 
intervention systematic reviews.  As such, wording was modified to be more relevant for DTA reviews (e.g. 
‘Index test’ rather than Intervention) 1,29. 
6. Eligibility 
criteria 
Language specific to DTA (modifying PICO as described for item 4 above) was added.   
8. Search The primary reason for modification is not specific to DTA, but all contemporary systematic reviews.  
When the original PRISMA was written, it was likely not feasible to publish all electronic strategies.  
Present day options for on-line supplemental material and institutional repositories now provide options to 
report all search strategies.  This will enhance transparency, improve replicability and ease systematic 
review updating. 
11. Data items Data items and relevant definitions with language specific to, and essential, regarding study objectives and 
risk of bias in DTA reviews (index test, target condition) were modified 16-18,39.  
12. Risk of bias in 
individual studies 
Individual studies of DTA may not only be at risk of bias, but there can also be concerns regarding 
applicability, as highlighted in QUADAS-2.  As such, language to reflect this was added 16.   
13. Summary 
measures 
1. Summary measures provided in PRISMA (e.g. risk ratios) are specific to systematic reviews of 
intervention effectiveness.  As such, wording was modified to reflect measures relevant to assessing 
diagnostic accuracy (e.g. sensitivity) 17,18.   
2. The unit of assessment [per-lesion (multiple samples included for every patient as individual data points 
in a 2x2 table, e.g. multiple liver lesions treated as individual observations) vs. per-patient] can be critical 
regarding accuracy estimates and generalizability of results due to potential bias introduced from clustering 
effect in per-lesion analysis 40; as such this additional requirement relevant to DTA reviews was added. 
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14. Synthesis of 
results 
1. Measures of consistency (e.g. I2) considered routine in intervention reviews are not typically applicable in 
DTA reviews; no consensus regarding alternative statistics presently exists.  As such, the more general 
term, ‘variability,’ which can reflect multiple strategies to explore variability, was used in place of 
‘inconsistency’ 8,10,15.   
2. Additional specific items particular to DTA reviews were felt to be of sufficient relevance to list as 
requirements.  These include describing definitions of the target condition and test positivity, among others 
17,18. 
18. Study 
characteristics 
Study characteristics felt to be essential regarding risk of bias and applicability in DTA systematic reviews 
were listed (e.g. reference standard, clinical setting) 29.  Funding sources was added in order to optimize 
transparency; industry vs. non-industry funding may be relevant to consider in DTA systematic reviews. 
19. Risk of bias 
within studies 
Please see comment for item 12. 
20. Results of 
individual studies 
Original wording was specific to systematic reviews of intervention effectiveness: ‘summary data for each 
intervention group’.  As such, the wording was revised to reflect results relevant to DTA reviews (e.g. 2x2 
data, positivity threshold used) 16-18.  2x2 data reporting is required to allow readers to evaluate important 
variables such as the proportion with the target condition, and other accuracy estimates that may not have 
been specifically addressed in the review (e.g. positive predictive value). 
21. Synthesis of 
results 
Language was modified to be more specific for and relevant to DTA systematic reviews e.g. ‘describe test 
accuracy’.  In addition, the term ‘inconsistency’ was replaced with the preferred term for DTA reviews 
‘variability’ as described for item 14 above. 
23. Additional 
analyses 
In addition to the original PRISMA wording, we ask that additional information (including potential harms) 
relevant to DTA systematic reviews be reported [e.g. index test failures (inconclusive, unusable or 
indeterminate results) and adverse events related to index test administration] 17,18.  
24. Summary of 
evidence 
Wording was simplified to only refer to ‘main findings’ since there is typically only one primary outcome 
in DTA systematic reviews (diagnostic accuracy).  In addition, relevance to key groups was considered to 
be more appropriate with item 26; as such, it was modified and moved there. 
25. Limitations As per discussion for item 12, wording was modified to reflect concerns regarding ‘applicability’ in 
addition to ‘risk of bias’ 16. 
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26. Conclusions As per discussion for item 24, implications for clinical practice were thought to be more appropriate in the 
conclusions.  In addition, language specific to generalizability of findings for DTA reviews (e.g. intended 
use and clinical role of the index test) was added 17,18 . 
 
22 
 
Table 2:  PRISMA-DTA Checklist. Legend: # - Original unmodified PRISMA item; #* - Modified original PRISMA item; D# - New 
PRISMA-DTA item.   Original PRISMA items 15 and 22 were omitted for reasons outlined in the text. 
Item Description 
Title/ Abstract 
1*. Title Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies. 
2*. Abstract Abstract: See PRISMA-DTA for abstracts. 
Introduction 
3. Rationale Describe the rationale for the review in the context of what is already known. 
D1.  Clinical role of index 
test 
State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the 
rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design). 
4*. Objectives Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s). 
Methods 
5. Protocol and registration Indicate where the review protocol can be accessed (e.g., Web address), and, if available, provide registration information 
including registration number.  
6*. Eligibility criteria Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study design) 
and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving ra tionale.  
7. Information sources Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched. 
8*. Search Present full search strategies for all electronic databases and other sources searched, including any limits used , such that they 
could be repeated. 
9. Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, inc luded in 
the meta-analysis). 
10. Data collection process Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators . 
11*. Definitions for data 
extraction 
Provide definitions used in data extraction and classifications  of target condition(s), index test(s), reference standard(s) and 
other characteristics (e.g. study design, clinical setting). 
12*. Risk of bias and 
applicability 
Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review 
question.  
13*. Diagnostic accuracy 
measures 
State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity, specificity) and state the unit of assessment (e.g. 
per-patient, per-lesion). 
14*. Synthesis of results Describe methods of handling data, combining results of studies and describing variability between studies. This could includ e, 
but is not limited to:  
a) handling of multiple definitions of target 
condition 
b) handling of multiple thresholds of test positivity 
c) handling multiple index test readers  
d) handling of indeterminate test results  
e) grouping and comparing tests  
f) handling of different reference standards  
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D2. Meta-analysis  Report the statistical methods used for meta-analyses, if performed. 
16. Additional analyses Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified. 
Results 
17. Study selection Give numbers of studies screened, assessed for eligibility, and included in the review, and, if applicable, included in the meta-
analysis, with reasons for exclusions at each stage, ideally with a flow diagram. 
18*. Study characteristics  For each included study provide citations and present key characteristics including:  
a) participant characteristics (presentation, prior testing) 
b) clinical setting 
c) study design 
d) target condition definition 
e) index test 
f) reference standard 
g) sample size  
h) funding sources 
19*.  Risk of bias and 
applicability 
Present evaluation of risk of bias and concerns regarding applicability for each study. 
20*. Results of individual 
studies 
For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 2x2 
data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or ROC plot. 
21*. Synthesis of results  Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals. 
23*. Additional analyses Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: 
failure rates, proportion of inconclusive results, adverse events). 
Discussion/ Conclusions  
24*. Summary Summarize the main findings including the strength of evidence. 
25*. Limitations Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review process 
(e.g. incomplete retrieval of identified research). 
26*. Conclusions Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research an d 
clinical practice (e.g. the intended use and clinical role of the index test). 
Other 
27. Funding Describe sources of funding for the systematic review and other support; role of funders for the systematic review. 
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Table 3: PRISMA-DTA for Abstracts Checklist.  
Legend: #, White = unmodified original PRISMA for Abstracts item; #* = modified 
original PRISMA for Abstracts item; A# = new PRISMA-DTA for Abstracts item.   
Original PRISMA for Abstracts item 8 was omitted for reasons outlined in the text. 
Item Description 
Title/ Purpose 
1*. Title:  Identify the report as a systematic review (+/- meta-analysis) of 
diagnostic test accuracy (DTA) studies. 
2*. Objectives:  The research question including components such as participants, index 
test(s), and target condition(s). 
Methods 
3*. Eligibility criteria:  Study characteristics used as criteria for eligibility. 
4. Information sources:  Key databases searched and search dates. 
5. Risk of bias and 
applicability: 
Methods of assessing risk of bias and applicability. 
A1. Synthesis of results  Methods for data synthesis  
Results 
6. Included studies:  Number and type of included studies and participants and relevant 
characteristics of studies (including reference standard).  
7*. Synthesis of results:  Results for analysis of diagnostic accuracy, preferably indicating the 
number of studies and participants. Describe test accuracy including 
variability; if meta-analysis was done, include summary results and 
confidence intervals. 
Discussion/ Conclusions 
9*. Strengths and Limitations:  Brief summary of the strength and limitations of the evidence. 
10. Interpretation:  General interpretation of the results and important implications. 
Other 
11. Funding:  Primary source of funding for the review.  
12. Registration:  Registration number and registry name. 
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